Welcome to our dedicated page for TherapeuticsMD news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on TherapeuticsMD stock.
TherapeuticsMD, Inc. (TXMD) is a pioneering pharmaceutical company dedicated to improving women's health through innovative products. The company focuses on creating solutions that address the unique health challenges women face at every stage of life. TherapeuticsMD's commitment to women's health is evident through its diverse product offerings and robust development pipeline. Key products include prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands, as well as hormone therapy treatments like IMVEXXY®, BIJUVA®, and ANNOVERA®.
The company operates primarily as a pharmaceutical royalty company, earning royalties from products licensed to other organizations with commercial capabilities in specific regions. Notably, TherapeuticsMD has granted Mayne Pharma an exclusive license to commercialize its key products in the United States and its territories. This strategic partnership ensures the broad distribution and accessibility of their therapies.
TherapeuticsMD's entrepreneurial spirit is matched by its clinical expertise, driving the development of next-generation solutions that go beyond existing treatments. The company remains agile and responsive to the needs of its customers, continually advancing its product lineup and enhancing the quality of care for women.
In terms of financial stability, TherapeuticsMD's royalties from licensed products provide a steady revenue stream, enabling further investment into research and development. This financial model supports sustainable growth and the continual advancement of women's healthcare solutions.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has settled its U.S. patent litigation concerning BIJUVA® with Amneal Pharmaceuticals. The settlement allows Amneal to commercially launch its generic version of BIJUVA by May 25, 2032, or sooner under specific conditions. The litigation had been ongoing since 2020 and stemmed from Amneal's attempt to market a generic variant before the patent expiration date of November 21, 2032. CEO Rob Finizio emphasizes the strength of the patent estate for BIJUVA, despite the early settlement.
TherapeuticsMD, Inc. (TXMD) reported Q3 2021 financial results, showing a total net product revenue of $24.5 million, up 41.1% from Q3 2020. ANNOVERA prescriptions rose by 62.7%, totaling 8,351 prescriptions. The company plans a $40 million cost reduction initiative for 2022, with an additional $20 million expected from divesting vitaCare. Hugh O'Dowd is appointed CEO. Despite revenue growth, the net loss increased to $47.4 million. Manufacturing issues related to ANNOVERA could impact future revenue covenants.
TherapeuticsMD has announced significant leadership changes, appointing Hugh O’Dowd as the new Chief Executive Officer, effective on or before December 31, 2021. He succeeds Robert G. Finizio, who will transition to Vice Chair of the Board. O’Dowd, previously President and CEO of Neon Therapeutics, has a strong track record in the pharmaceutical industry. Finizio expressed confidence in O’Dowd's capabilities to advance the company’s growth and mission in women’s healthcare, addressing unique challenges throughout various life stages.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will announce its third quarter 2021 financial results on November 11, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET on the same day, providing insights into the results and business updates. Investors can access the call by dialing 866-665-9531 (US) or 724-987-6977 (international) with Conference ID 6341637. A live webcast will also be available on the company's website, with a replay accessible for 30 days.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Mark Glickman as its new Chief Business Officer. Glickman, who has extensive experience in commercial roles at various pharmaceutical companies, will receive 660,000 restricted stock units (RSUs) and 260,000 performance stock units (PSUs) as part of his inducement package. The RSUs will vest over three years, while the PSUs are tied to revenue performance metrics. The appointment is part of the company's strategy to strengthen its leadership in women's healthcare.
Theramex has launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) in Europe and the UK. This body-identical hormone therapy is the first of its kind for post-menopausal women with intact uterus, aimed at alleviating symptoms of estrogen deficiency. Unlike synthetic hormones, Bijuva® and Bijuve® are chemically identical to natural hormones, associated with lower health risks. Clinical trials show significant improvements in vasomotor symptoms and quality of life during treatment, making it a vital option for women seeking effective HRT.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is recognizing Menopause Awareness Month to empower the 64 million U.S. women currently in menopause. With over 80% experiencing symptoms, the company highlights vulvar and vaginal atrophy (VVA), affecting more than half of menopausal women. The 'Take Pause' initiative includes educational videos featuring Dr. Rebecca Brightman to raise awareness about VVA and available treatments such as IMVEXXY. This effort aims to normalize discussions around menopause and its symptoms, encouraging women to seek care.
TherapeuticsMD (NASDAQ: TXMD) announced that CMS confirmed a permanent product-specific HCPCS J Code for ANNOVERA, effective October 1, 2021. This new coding will enable Title X Family Planning clinics to gain reimbursement for dispensing ANNOVERA, streamlining billing processes for approximately 4,900 facilities. The J Code is unique to ANNOVERA, enhancing patient access to the only yearly, patient-controlled vaginal contraceptive in the market. This development reflects a push towards improving women's healthcare accessibility.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced the appointment of Hugh O’Dowd as President, succeeding John C.K. Milligan, IV, now CEO of vitaCare Prescription Services. O’Dowd brings over 20 years of experience, notably at Novartis, and aims to enhance the company's value and commercialization efforts in women's health. The company also plans to grant O’Dowd 2.75 million RSUs and PSUs as part of his inducement. The management change reflects a strategic move to strengthen leadership in advancing TherapeuticsMD's portfolio.
TherapeuticsMD (TXMD) reported second-quarter 2021 financial results, highlighting a strong growth in net product revenues amounting to $23 million, up from $10.7 million in Q2 2020. Key products ANNOVERA and IMVEXXY saw substantial revenue increases of 202% and 56%, respectively. The company also noted progress in prescription growth and access to telemedicine. Despite a net loss of $42.7 million, up from $39.4 million in Q1 2021, cash on hand rose to $111.4 million. The firm is exploring investment opportunities in vitaCare, aiming for non-dilutive capital options.
FAQ
What is the current stock price of TherapeuticsMD (TXMD)?
What is the market cap of TherapeuticsMD (TXMD)?
What does TherapeuticsMD, Inc. do?
What products are offered by TherapeuticsMD?
Who commercializes TherapeuticsMD's products?
What type of company is TherapeuticsMD?
What is IMVEXXY?
What is BIJUVA?
What is ANNOVERA?
How does TherapeuticsMD generate revenue?
What are vitaMedMD and BocaGreenMD?
How does TherapeuticsMD contribute to women's health?
